• Member News

£30k award for international 3Rs prize - competition now open

The annual international 3Rs award, sponsored by the NC3Rs and GlaxoSmithKline, recognises primary research which has made a significant contribution to advancing the 3Rs in medical, biological or veterinary sciences.

Cell and Gene Therapy Catapult research highlights the UK’s growing global leadership in innovative cell and gene therapy industry

New research revealed by the Cell and Gene Therapy (CGT) Catapult today, indicates that the UK cell and gene therapy industry continues to expand, as the UK establishes itself as a global leader in the development of living medicines.

Purolite Selects Repligen’s Market-Leading OPUS® Pre-Packed Columns

High-Performance Praesto® Protein A and Ion Exchange Chromatography Resins paired with Leading OPUS® Technology

Arecor strengthens the patent portfolio of its formulation technology for the development of novel vaccine and gene therapy products

• Notification of an ‘intention to grant’ patent protecting Arecor’s novel approach to enabling stable liquid adenovirus formulations, has been received from both the European and US patent offices

Cell and Gene Therapy Catapult Annual Review Reveals Burgeoning UK Cell and Gene Medicines Sector

In its 2017 Annual Review published today, the Cell and Gene Therapy Catapult (CGT Catapult) shares an overview of its work over the past year as it increases its contribution to the UK’s thriving cell and gene therapy sector.

Horizon Discovery partners with The Michael J. Fox Foundation to introduce novel pre-clinical models for Parkinson’s Disease

Innovative and relevant models for understanding alpha-synuclein biology and Parkinson’s disease pathogenesis in vivo

SYGNIS AG announces the launch of the Universal Lateral Flow Assay kit and associated patent filing

Unique kit enables the fast and easy development of customized sandwich lateral flow assays

Locate Therapeutics Receives Biomedical Catalyst Primer Award To Develop Personalised Cell Therapies For Compromised Patient Populations

Locate Therapeutics' IntraStem Intracellular Delivery System offers the possibility of increasing MSC transfection rates by up to 200% Combined with the TAOS Matrix, IntraStem can deliver antibodies, magnetic nanoparticles (MNPs) and nucleic acids (plasmid (p)DNA, mRNA and siRNA) into cells at much higher levels than the current alternatives for reprogramming, as well as improving gene editing, using for example, the CRISPR-cas9 approach

Scancell appoints Dr Cliff Holloway as Chief Executive Officer

Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the appointment of Dr Cliff Holloway as Chief Executive Officer of Scancell, starting 10 January 2018. Cliff will seek to drive progress of Scancell’s immunotherapy platforms ImmunoBody® and Moditope® and oversee their commercialisation. Cliff succeeds Richard Goodfellow who will remain on the Company’s Board of Directors.

Synpromics wins best emerging UK synthetic biotech company at OBN Awards

Synpromics is thrilled to announce they have been awarded Best Emerging UK Synthetic Biotech Company at the 9th Annual OBN Awards